Cited by 3,848Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and TreatmentCancer Treatment and Pharmacology

The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Moore, Malcolm J., Goldstein, David, Hamm, John, Figer, Arie, Hecht, Joel R., Gallinger, Steven, Au, Heather J., Murawa, Pawel, Walde, David, Wolff, Robert A., Campos, Daniel, Lim, Robert, Ding, Keyue, Clark, Gary, Voskoglou-Nomikos, Theodora, Ptasynski, Mieke, Parulekar, Wendy·2007·Journal of Clinical Oncology

DOI 10.1200/jco.2006.07.9525

Open this paper in CoChat — free account

Abstract

Purpose: Patients with advanced pancreatic cancer have a poor prognosis and there have been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic tumors often overexpress human epidermal growth factor receptor type 1 (HER1/EGFR) and this is associated with a worse prognosis. We studied the effects of adding the HER1/EGFR-targeted agent erlotinib to gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer. Patients and Methods: Patients were randomly assigned 1:1 to receive standard gemcitabine plus erlotinib (100 or 150 mg/d orally) or gemcitabine plus placebo in a double-blind, international phase III trial. The primary end point was overall survival. Results: A total of 569 patients were randomly assigned. Overall survival based on an intent-to-treat analysis was significantly prolonged on the erlotinib/gemcitabine arm with a hazard ratio (HR) of 0.82 (95% CI, 0.69 to 0.99; P = .038, adjusted for stratification factors; median 6.24 months v 5.91 months). One-year survival was also greater with erlotinib plus gemcitabine (23% v 17%; P = .023). Progression-free survival was significantly longer with erlotinib plus gemcitabine with an estimated HR of 0.77 (95% CI, 0.64 to 0.92; P = .004). Objective response rates were not significantly different between the arms, although more patients on erlotinib had disease stabilization. There was a higher incidence of some adverse events with erlotinib plus gemcitabine, but most were grade 1 or 2. Conclusion: To our knowledge, this randomized phase III trial is the first to demonstrate statistically significantly improved survival in advanced pancreatic cancer by adding any agent to gemcitabine. The recommended dose of erlotinib with gemcitabine for this indication is 100 mg/d.

Integrity signals

Registry

Crossref · 10.1200/jco.2006.07.9525

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895
Self-citation
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citation
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Cancer Statistics, 2005
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J., Hickey, H., Beger, H. G., Fernández‐Cruz, L., Dervenis, C., LACAINE, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,709
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J. M., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,418
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Tsao, M., Sakurada, A., Cutz, J.-C., Zhu, C., Kamel‐Reid, S., Squire, J. A., Lorimer, I. A. J., Zhang, T., Liu, G., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,815
Self-citation
Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies
Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001

Show all 49 references

Sorted by citations

Items 601–700 of 1,008

Clinical, Molecular and Genetic Validation of a Murine Orthotopic Xenograft Model of Pancreatic Adenocarcinoma Using Fresh Human Specimens
Walters, D. M., Stokes, J. B., Adair, S. J., Stelow, E. B., Borgman, C. A., Lowrey, B. T., Xin, W., Blais, E. M., Lee, J. K., Papin, J. A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077065 · Cited by 76
Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials
Qi, W., Sun, Y., Shen, Z., & Yao, Y. (2014) · Journal of Chemotherapy · doi:10.1179/1973947814y.0000000189 · Cited by 76
Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals
Kletzl, H., Giraudon, M., Ducray, P. S., Abt, M., Hamilton, M., & Lum, B. L. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000212 · Cited by 78
Pancreatic Cancer Clinical Trials and Accrual in the United States
Hoos, W. A., James, P. M., Rahib, L., Talley, A. W., Fleshman, J. M., & Matrisian, L. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.4823 · Cited by 74
Cytotoxic effects of gemcitabine-loaded solid lipid nanoparticles in pancreatic cancer cells
Affram, K., Smith, T., Ofori, E., Krishnan, S., Underwood, P. W., Trevino, J. G., & Agyare, E. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.101374 · Cited by 75
Autophagy-related microRNAs: Possible regulatory roles and therapeutic potential in and gastrointestinal cancers
Pourhanifeh, M. H., Vosough, M., Mahjoubin‐Tehran, M., Hashemipour, M., Nejati, M., Abbasi‐Kolli, M., Sahebkar, A., & Mirzaei, H. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105133 · Cited by 76
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial
Assénat, E., Azria, D., Mollévi, C., Guimbaud, R., Tubiana-Mathieu, N., Smith, D. M., Delord, J., Samalin, E., Portales, F., Larbouret, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3473 · Cited by 77
α-Mangostin: A Dietary Antioxidant Derived from the Pericarp of Garcinia mangostana L. Inhibits Pancreatic Tumor Growth in Xenograft Mouse Model
Hafeez, B. B., Mustafa, A., Fischer, J. W., Singh, A. K., Zhong, W., Shekhani, M. O., Meske, L. M., Havighurst, T. C., Kim, K., & Verma, A. K. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5212 · Cited by 77
Substrate‐dependent bidirectional modulation of P‐glycoprotein‐mediated drug resistance by erlotinib
Noguchi, K., Kawahara, H., Kaji, A., Katayama, K., Mitsuhashi, J., & Sugimoto, Y. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01213.x · Cited by 75
Does Health-Related Quality of Life Improve for Advanced Pancreatic Cancer Patients Who Respond to Gemcitabine? Analysis of a Randomized Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Romanus, D., Kindler, H. L., Archer, L. E., Basch, E., Niedzwiecki, D., Weeks, J. C., & Schrag, D. (2011) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2011.09.001 · Cited by 75
A Phase I Clinical Trial of Vaccination With KIF20A-derived Peptide in Combination With Gemcitabine For Patients With Advanced Pancreatic Cancer
Suzuki, N., Hazama, S., Ueno, T., Matsui, H., Shindo, Y., Iida, M., Yoshimura, K., Yoshino, S., Takeda, K., & Oka, M. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000012 · Cited by 76
Risk of Incremental Toxicities and Associated Costs of New Anticancer Drugs: A Meta-Analysis
Niraula, S., Amir, E., Vera-Badillo, F., Šeruga, B., Ocaña, A., & Tannock, I. F. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.8437 · Cited by 79
Current Knowledge on Pancreatic Cancer
Iovanna, J., Mallmann, M. C., Gonçalvès, A., Turrini, O., & Dagorn, J. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00006 · Cited by 74
Phase II Study of Dasatinib (BMS-354825) in Patients With Metastatic Adenocarcinoma of the Pancreas
Chee, C. E., Krishnamurthi, S., Nock, C. J., Meropol, N. J., Gibbons, J., Fu, P., Bokar, J. A., Teston, L., O'Brien, T., Gudena, V. K., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0255 · Cited by 75
Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?
Sun, C. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i35.4944 · Cited by 75
Aptamer-Mediated Delivery of Chemotherapy to Pancreatic Cancer Cells
Ray, P., Cheek, M. A., Sharaf, M. L., Li, N., Ellington, A. D., Sullenger, B. A., Shaw, B. R., & White, R. R. (2012) · Nucleic Acid Therapeutics · doi:10.1089/nat.2012.0353 · Cited by 76
Resveratrol and capsaicin used together as food complements reduce tumor growth and rescue full efficiency of low dose gemcitabine in a pancreatic cancer model
Vendrely, V., Peuchant, E., Buscail, É., Moranvillier, I., Rousseau, B., Bedel, A., Brillac, A., de Verneuil, H., Moreau‐Gaudry, F., & Dabernat, S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.002 · Cited by 79
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial
Middleton, G., Palmer, D. H., Greenhalf, W., Ghaneh, P., Jackson, R., Cox, T. F., Evans, A. G., Shaw, V. E., Wadsley, J., Valle, J. W., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30084-0 · Cited by 75
Determinants of RASistance to Anti–Epidermal Growth Factor Receptor Agents
Baselga, J. M., & Rosen, N. X. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.3700 · Cited by 76
Targeting EGFR resistance networks in head and neck cancer
Ratushny, V., Astsaturov, I. A., Burtness, B. A., Golemis, E. A., & Silverman, J. S. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.02.021 · Cited by 76
Synergistic Effect between Erlotinib and MEK Inhibitors in KRAS Wild-Type Human Pancreatic Cancer Cells
Diep, C. H., Muñoz, R. M., Choudhary, A. K., Hoff, D. D. V., & Han, H. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2214 · Cited by 74
ERK1/2 activity contributes to gemcitabine resistance in pancreatic cancer cells
Zheng, C., Jiao, X., Jiang, Y., & Sun, S. (2013) · Journal of International Medical Research · doi:10.1177/0300060512474128 · Cited by 74
The Winning Formulation: The Development of Paclitaxel in Pancreatic Cancer
Ma, W. W., & Hidalgo, M. M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1356 · Cited by 74
EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer
Levy, M. J., Alberts, S. R., Bamlet, W. R., Burch, P. A., Farnell, M. B., Gleeson, F. C., Haddock, M. G., Kendrick, M. L., Oberg, A. L., Petersen, G. M., et al. (2016) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2016.11.014 · Cited by 74
Extracellular vesicles as mediators of the progression and chemoresistance of pancreatic cancer and their potential clinical applications
Qiu, J., Yang, G., Feng, M., Zheng, S., Cao, Z., You, L., Zheng, L., Zhang, T., & Zhao, Y. (2018) · Molecular Cancer · doi:10.1186/s12943-017-0755-z · Cited by 77
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer
Spano, C., Grisendi, G., Golinelli, G., Rossignoli, F., Prapa, M., Bestagno, M., Candini, O., Petrachi, T., Recchia, A., Miselli, F., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-37433-6 · Cited by 76
Progress in the Treatment of Metastatic Pancreatic Cancer and the Search for Next Opportunities
Ko, A. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7625 · Cited by 74
Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma
Olson, P., Chu, G. C., Perry, S. R., Nolan-Stevaux, O., & Hanahan, D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111079108 · Cited by 73
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
Ko, A. H., Venook, A. P., Bergsland, E. K., Kelley, R. K., Korn, W. M., Dito, E., Schillinger, B., Scott, J. H., Hwang, J. J., & Tempero, M. A. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1257-5 · Cited by 73
Treatment of Advanced Pancreatic Cancer
Ducreux, M. P., Boige, V., & Malka, D. (2007) · Seminars in Oncology · doi:10.1053/j.seminoncol.2007.01.006 · Cited by 73
Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
Garrido‐Laguna, I., Tan, A. C., Uson, M. L., Angenendt, M., W, W., Villaroel, M. C., Zhao, M., Rajeshkumar, N. V., Jimeno, A., Donehower, R. C., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605819 · Cited by 78
Ack1 Tyrosine Kinase Activation Correlates with Pancreatic Cancer Progression
Mahajan, K. N., Coppola, D., Chen, Y. A., Zhu, W., Lawrence, H. R., Lawrence, N. J., & Mahajan, N. P. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.12.028 · Cited by 73
EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance
Sevelda, F., Mayr, L., Kubista, B., Lötsch, D., van Schoonhoven, S., Windhager, R. H., Pirker, C., Micksche, M., & Berger, W. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0251-5 · Cited by 74
BMS-754807, a Small-Molecule Inhibitor of Insulin-like Growth Factor-1 Receptor/Insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer
Awasthi, N., Zhang, C., Ruan, W., Schwarz, M. A., & Schwarz, R. E. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0447 · Cited by 73
Effective targeting of gemcitabine to pancreatic cancer through PEG-cored Flt-1 antibody-conjugated dendrimers
Öztürk, K., Esendağlı, G., Gürbüz, M. U., Tülü, M., & Çalış, S. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.12.009 · Cited by 73
A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance
Lee, H. S., Park, S. B., Kim, S. A., Kwon, S. K., Cha, H., Lee, D. Y., Ro, S., Cho, J. M., & Song, S. Y. (2017) · Scientific Reports · doi:10.1038/srep41615 · Cited by 76
Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway
Namba, T., Kodama, R., Moritomo, S., Hoshino, T., & Mizushima, T. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.172 · Cited by 73
Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer
Blomstrand, H., Scheibling, U., Bratthäll, C., Gréen, H., & Elander, N. O. (2019) · BMC Cancer · doi:10.1186/s12885-018-5244-2 · Cited by 69
Erlotinib loaded chitosan nanoparticles: Formulation, physicochemical characterization and cytotoxic potential
Pandey, P., Dua, K., & Dureja, H. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.08.084 · Cited by 72
Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer
Zaborowska-Szmit, M., Krzakowski, M. J., Kowalski, D. M., & Szmit, S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051268 · Cited by 73
Small extracellular vesicle non-coding RNAs in pancreatic cancer: molecular mechanisms and clinical implications
Reese, M., & Dhayat, S. A. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01149-4 · Cited by 73
Advances and Prospects in the Treatment of Pancreatic Cancer
Duan, H., li, L., & He, S. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s413496 · Cited by 92
In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting with Cetuximab/Trastuzumab Is More Effective than Treatment with Trastuzumab/Erlotinib or Lapatinib Alone: Implication of Receptors' Down-regulation and Dimers' Disruption
Larbouret, C., Gaborit, N., Chardès, T., Coelho, M., Campigna, E., Mollévi, C., Mach, J., Azria, D., Robert, B., & Pèlegrin, A. (2012) · Neoplasia · doi:10.1593/neo.111602 · Cited by 74
Drug-biomarker co-development in oncology – 20 years and counting
Twomey, J. D., Brahme, N. N., & Zhang, B. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.02.002 · Cited by 75
Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications
Imperial, R. J. L., Toor, O. M., Hussain, A., Subramanian, J., & Masood, A. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.016 · Cited by 74
Gemcitabine-Induced Reversible Posterior Leukoencephalopathy Syndrome: A Case Report and Review of the Literature
Rajasekhar, A., & George, T. J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-11-1332 · Cited by 72
Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma
Fogelman, D. R., Sugar, E. A., Oliver, G. R., Shah, N. N., Klein, A. P., Alewine, C., Wang, H., Javle, M. M., Shroff, R. T., Wolff, R. A., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2788-6 · Cited by 72
Self-citation
Identification of Anti-Malarial Compounds as Novel Antagonists to Chemokine Receptor CXCR4 in Pancreatic Cancer Cells
Kim, J., Yip, M. L. R., Shen, X., Li, H., Hsin, L.-Y. C., LaBarge, S. A., Heinrich, E. L., Lee, W., Lu, J., & Vaidehi, N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031004 · Cited by 73
Developing effective combination therapy for pancreatic cancer: An overview
Miller, A. L., Garcia, P. L., & Yoon, K. J. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104740 · Cited by 73
SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer
Botta, G. P., Kato, S., Patel, H., Fanta, P. T., Lee, S., Okamura, R., & Kurzrock, R. (2021) · JCI Insight · doi:10.1172/jci.insight.150453 · Cited by 71
The molecular biology and novel treatments of vestibular schwannomas
Fong, B., Barkhoudarian, G., Pezeshkian, P., Parsa, A. T., Gopen, Q. S., & Yang, I. (2011) · Journal of neurosurgery · doi:10.3171/2011.6.jns11131 · Cited by 70
Phase I Trial of Erlotinib-Based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer
Choong, N. W., Mauer, A. M., Haraf, D. J., Lester, E. P., Hoffman, P. C., Kozloff, M. F., Lin, S., Dancey, J. E., Szeto, L. L., Grushko, T. A., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31818396a4 · Cited by 70
Human Mena+11a Isoform Serves as a Marker of Epithelial Phenotype and Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Pancreatic Cancer Cell Lines
Pino, M. S., Balsamo, M., Modugno, F. D., Mottolese, M., Alessio, M., Melucci, E., Milella, M., McConkey, D. J., Philippar, U., Gertler, F. B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0436 · Cited by 70
Disrupting Cytokine Signaling in Pancreatic Cancer
Wu, C. S.-Y., Fernández, S., Criswell, T., Chidiac, T. A., Guttridge, D. C., Villalona-Calero, M. A., & Bekaii‐Saab, T. (2013) · Pancreas · doi:10.1097/mpa.0b013e318279b87f · Cited by 70
Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer
Cella, D. F., Butt, Z. A., Kindler, H. L., Fuchs, C. S., Bray, S. L., Barlev, A., & Oglesby, A. K. (2012) · Quality of Life Research · doi:10.1007/s11136-012-0217-4 · Cited by 70
EGFR inhibition in the treatment of non‐small cell lung cancer
Gerber, D. E. (2008) · Drug Development Research · doi:10.1002/ddr.20268 · Cited by 70
Systemic Chemotherapy in Advanced Pancreatic Cancer
Lee, H. S., & Park, S. W. (2016) · Gut and Liver · doi:10.5009/gnl15465 · Cited by 73
Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?
Saad, E. D., Zalcberg, J. R., Péron, J., Coart, E., Burzykowski, T., & Buyse, M. E. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx179 · Cited by 70
EGFRvIII: An Oncogene with Ambiguous Role
Rutkowska, A., Stoczyńska-Fidelus, E., Janik, K., Włodarczyk, A., & Rieske, P. (2019) · Journal of Oncology · doi:10.1155/2019/1092587 · Cited by 71
Nimotuzumab: beyond the EGFR signaling cascade inhibition
Mazorra, Z., Chao, L., Lavastida, A., Sanchez, B., Ramos, M., Iznaga, N., & Crombet, T. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.04.008 · Cited by 74
Combining Gemcitabine-Loaded Macrophage-like Nanoparticles and Erlotinib for Pancreatic Cancer Therapy
Cai, H., Wang, R., Guo, X., Song, M., Yan, F., Ji, B., & Liu, Y. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c01225 · Cited by 70
3D tumor spheroid microarray for high-throughput, high-content natural killer cell-mediated cytotoxicity
Gopal, S., Kwon, S., Ku, B., Lee, D. W., Kim, J., & Dordick, J. S. (2021) · Communications Biology · doi:10.1038/s42003-021-02417-2 · Cited by 68
Structure–Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017–Present)
Șandor, A., Ionuţ, I. A., Marc, G., Oniga, I., Eniu, D. T., & Oniga, O. (2023) · Pharmaceuticals · doi:10.3390/ph16040534 · Cited by 79
Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001)
Dragovich, T., Laheru, D. A., Dayyani, F., Bolejack, V., Smith, L., Seng, J., Burris, H. A., Rosen, P. J., Hidalgo, M. M., Ritch, P. S., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2499-4 · Cited by 69
Annexin II Overexpression Predicts Rapid Recurrence after Surgery in Pancreatic Cancer Patients Undergoing Gemcitabine-Adjuvant Chemotherapy
Takano, S., Togawa, A., Yoshitomi, H., Shida, T., Kimura, F., Shimizu, H., Yoshidome, H., Ohtsuka, M., Kato, A., Tomonaga, T., et al. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0061-5 · Cited by 69
Developments in metastatic pancreatic cancer: Is gemcitabine still the standard?
Ying, J. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i8.736 · Cited by 69
Oral Anticancer Drugs: How Limited Dosing Options and Dose Reductions May Affect Outcomes in Comparative Trials and Efficacy in Patients
Prasad, V. K., Massey, P. R., & Fojo, T. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0204 · Cited by 69
Sterol regulatory element-binding protein 1 inhibitors decrease pancreatic cancer cell viability and proliferation
Siqingaowa, Sekar, S., Gopalakrishnan, V., & Taghibiglou, C. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.05.023 · Cited by 69
Adrenocortical carcinoma: The management of metastatic disease
Fay, A. P., Elfiky, A. A., Teló, G. H., McKay, R. R., Kaymakcalan, M. D., Nguyen, P. L., Vaidya, A., Ruan, D. T., Joaquim Bellmunt, B., & Choueiri, T. K. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.05.009 · Cited by 69
CC Chemokine Receptor 2-Targeting Copper Nanoparticles for Positron Emission Tomography-Guided Delivery of Gemcitabine for Pancreatic Ductal Adenocarcinoma
Zhang, X., Detering, L., Sultan, D. H., Luehmann, H. P., Li, L., Heo, G. S., Zhang, X., Lou, L., Grierson, P. M., Greco, S., et al. (2021) · ACS Nano · doi:10.1021/acsnano.0c08185 · Cited by 69
Comorbidity, age and overall survival in patients with advanced pancreatic cancer – Results from NCIC CTG PA.3: A phase III trial of gemcitabine plus erlotinib or placebo
Vickers, M. M., Powell, E. D., Asmis, T. R., Jonker, D. J., Hilton, J. F., O’Callaghan, C. J., Tu, D., Parulekar, W. R., & Moore, M. J. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.035 · Cited by 68
Self-citation
Phase II Trial of Gemcitabine, Irinotecan, and Celecoxib in Patients With Advanced Pancreatic Cancer
Lipton, A., Campbell‐Baird, C., Witters, L. M., Harvey, H. A., & Ali, S. M. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181cda097 · Cited by 68
Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
Strumberg, D., Schultheis, B. S., Scheulen, M. E., Hilger, R. A., Krauss, J., Marschner, N. W., Lordick, F., Bach, F., Reuter, D., Edler, L., et al. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9619-8 · Cited by 68
Regular Dose of Gemcitabine Induces an Increase in CD14+ Monocytes and CD11c+ Dendritic Cells in Patients with Advanced Pancreatic Cancer
Soeda, A., Morita‐Hoshi, Y., Makiyama, H., Morizane, C., Ueno, H., Ikeda, M., Okusaka, T., Yamagata, S., Takahashi, N. K., Hyodo, I., et al. (2009) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyp112 · Cited by 68
Skeletal metastases in pancreatic cancer: a retrospective study and review of the literature.
Borad, M. J., Saadati, H., Lakshmipathy, A., Campbell, E., Hopper, P., Jameson, G., Hoff, D. D. V., & Saif, M. W. (2009) · Europe PMC (PubMed Central) · Cited by 68
Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial
Boeck, S. H., Weigang-Köhler, K., Fuchs, M., Kettner, E., Quietzsch, D., Trojan, J., Stötzer, O. J., Zeuzem, S., Lordick, F., Köhne, C.-H., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl463 · Cited by 68
Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs
Amir, E., Šeruga, B., Martínez‐López, J., Kwong, R. C., Pandiella, A., Tannock, I. F., & Ocaña, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.2393 · Cited by 68
Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor
McCaffery, I., Tudor, Y., Deng, H., Tang, R., Suzuki, S., Badola, S., Kindler, H. L., Fuchs, C. S., Loh, E. Y., Patterson, S. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1840 · Cited by 68
Phase I and Pharmacokinetic Study of Erlotinib for Solid Tumors in Patients With Hepatic or Renal Dysfunction: CALGB 60101
Miller, A. A., Murry, D. J., Owzar, K., Hollis, D. R., Lewis, L. D., Kindler, H. L., Marshall, J. L., Villalona-Calero, M. A., Edelman, M. J., Hohl, R. J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6210 · Cited by 68
Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer
Liu, H. Y., Yu, X., Liu, H., Wu, D., & She, J. (2016) · Scientific Reports · doi:10.1038/srep30346 · Cited by 70
Ethical, Scientific, and Regulatory Perspectives Regarding the Use of Placebos in Cancer Clinical Trials
Daugherty, C. K., Ratain, M. J., Emanuel, E. J., Farrell, A. T., & Schilsky, R. L. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5335 · Cited by 68
Randomized phase II – study evaluating EGFR targeting therapy with Cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer – PARC: study protocol [ISRCTN56652283]
Krempien, R. C., Muenter, M. W., Huber, P., Nill, S., Friess, H., Timke, C., Didinger, B. H., Buechler, P., Heeger, S., Herfarth, K. K., et al. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-131 · Cited by 68
Modest Improvement in Overall Survival for Patients With Metastatic Pancreatic Cancer
Worni, M., Güller, U., White, R. R., Castleberry, A. W., Pietrobon, R. S., Cerny, T., Gloor, B., & Koeberle, D. (2013) · Pancreas · doi:10.1097/mpa.0b013e318291fbc5 · Cited by 83
The Cost-Effectiveness of Neoadjuvant Chemoradiation is Superior to a Surgery-First Approach in the Treatment of Pancreatic Head Adenocarcinoma
Abbott, D. E., Tzeng, C.-W. D., Merkow, R. P., Cantor, S. B., Chang, G. J., Katz, M. H. G., Bentrem, D. J., Bilimoria, K. Y., Crane, C. H., Varadhachary, G. R., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-2882-0 · Cited by 67
Self-citation
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors
Tolcher, A. W., LoRusso, P. M., Arzt, J. A., Busman, T. A., Lian, G., Rudersdorf, N. S., Vanderwal, C. A., Kirschbrown, W. P., Holen, K. D., & Rosen, L. S. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2883-8 · Cited by 68
Long‐term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer
Arvold, N. D., Ryan, D. P., Niemierko, A., Blaszkowsky, L. S., Kwak, E. L., Wo, J. Y.-L., Allen, J. N., Clark, J. W., Wadlow, R. C., Zhu, A. X., et al. (2011) · Cancer · doi:10.1002/cncr.26633 · Cited by 67
A Cancer and Leukemia Group B Phase II Study of Sunitinib Malate in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma (CALGB 80603)
O'Reilly, E. M., Niedzwiecki, D., Hall, M., Hollis, D. R., Bekaii‐Saab, T., Pluard, T., Douglas, K., Abou‐Alfa, G. K., Kindler, H. L., Schilsky, R. L., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0152 · Cited by 67
Advancements in the Management of Pancreatic Cancer: 2013
Saif, M. W. (2013) · PubMed · doi:10.6092/1590-8577/1481 · Cited by 67
Does chemotherapy improve health-related quality of life in advanced pancreatic cancer? A systematic review
Kristensen, A., Vagnildhaug, O. M., Grønberg, B. H., Kaasa, S., Laird, B. J. A., & Solheim, T. S. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.01.006 · Cited by 68
Gemcitabine treatment promotes immunosuppressive microenvironment in pancreatic tumors by supporting the infiltration, growth, and polarization of macrophages
Deshmukh, S. K., Tyagi, N., Khan, M. A., Srivastava, S. K., AL-Ghadhban, A., Dugger, K. J., Carter, J. E., Singh, S., & Singh, A. P. (2018) · Scientific Reports · doi:10.1038/s41598-018-30437-2 · Cited by 67
FOLFIRINOX for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: The Royal Marsden Experience
Moorcraft, S. Y., Khan, K. H., Peckitt, C., Watkins, D. J., Rao, S., Cunningham, D., & Chau, I. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.09.005 · Cited by 68
PARP-1 Regulates Resistance of Pancreatic Cancer to TRAIL Therapy
Yuan, K., Sun, Y., Zhou, T., McDonald, J. M., & Chen, Y. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0516 · Cited by 67
Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy
Hamada, T., Nakai, Y., Yasunaga, H., Isayama, H., Matsui, H., Takahara, N., Sasaki, T., Takagi, K., Watanabe, T., Yagioka, H., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.131 · Cited by 70
Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma
Toll, A. D., Dasgupta, A., Potoczek, M., Yeo, C. J., Kleer, C. G., Brody, J. R., & Witkiewicz, A. K. (2010) · Human Pathology · doi:10.1016/j.humpath.2010.03.004 · Cited by 67
Cytotoxic Therapy for Advanced Pancreatic Adenocarcinoma
O'Reilly, E. M., & Abou‐Alfa, G. K. (2007) · Seminars in Oncology · doi:10.1053/j.seminoncol.2007.05.009 · Cited by 66
Radiosensitization of Epidermal Growth Factor Receptor/HER2–Positive Pancreatic Cancer Is Mediated by Inhibition of Akt Independent of Ras Mutational Status
Kimple, R. J., Vaseva, A. V., Cox, A. D., Baerman, K. M., Calvo, B. F., Tepper, J. E., Shields, J. M., & Sartor, C. I. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1324 · Cited by 66
Epidermal Growth Factor Receptor Inhibitors: Coming of Age
Mahipal, A., Kothari, N., & Gupta, S. (2014) · Cancer Control · doi:10.1177/107327481402100111 · Cited by 69
An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoring
Péron, J., Buyse, M. E., Ozenne, B., Roche, L., & Roy, P. (2016) · Statistical Methods in Medical Research · doi:10.1177/0962280216658320 · Cited by 66
Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease
ter Veer, E., van Rijssen, L. B., Besselink, M. G., Mali, R. M. A., Berlin, J. D., Boeck, S. H., Bonnetain, F., Chau, I., Conroy, T., Cutsem, E. V., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30098-6 · Cited by 66
Self-citation
Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question—Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head
Abrams, R. A., Winter, K. A., Safran, H. P., Goodman, K. A., Regine, W. F., Berger, A. C., Gillin, M. T., Philip, P. A., Lowy, A. M., Wu, A. J.-C., et al. (2020) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000633 · Cited by 66

Authors: Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., Campos, D., Lim, R., Ding, K., Clark, G., Voskoglou-Nomikos, T., Ptasynski, M., & Parulekar, W.
Affiliations: Norton Healthcare (US)
From the Divisions of Medical Oncology, Hematology, and Surgical Oncology, Princess Margaret Hospital, Toronto; National Cancer Institute of Canada Clinical Trials Group, Kingston; Algoma District Cancer Program, Sault Ste Marie, Ontario; Cross Cancer Institute, Edmonton, Alberta, Canada; the Australasian Gastrointestinal Tumor Group, Sydney, Australia; Norton Healthcare Pavilion, Louisville, KY; UCLA Medical Center, Los Angeles, CA; M. D. Anderson Cancer Centre, Houston, TX; OSI Pharmaceuticals, Boulder...
ORCID: Moore, Malcolm J.
Goldstein, David
Hamm, John
Hecht, Joel R.
Au, Heather J.
Wolff, Robert A.
Ding, Keyue
Clark, Gary
Parulekar, Wendy
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2007-05-20
Volume: 25
Issue: 15
Pages: 1960-1966
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2006.07.9525
OpenAlex: W2158134441
Cited by: 3,848
References: 49
Citations by year: 2026: 45 · 2025: 62 · 2024: 123 · 2023: 113 · 2022: 129 · 2021: 178 · 2020: 159 · 2019: 170 · 2018: 204 · 2017: 217 · 2016: 242 · 2015: 275 · 2014: 274 · 2013: 251 · 2012: 268
FWCI: 133.78
Type: journal article
Language: en
Update notices: new_edition (2023-10-17)
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
Keywords: erlotinib, gemcitabine, advanced pancreatic cancer, targeted therapy, overall survival, progression-free survival, metastatic pancreatic cancer, combination chemotherapy, adverse events
MeSH terms: Erlotinib Hydrochloride, Gemcitabine, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Double-Blind Method, Female, Humans, International Agencies, Male, Middle Aged, Pancreatic Neoplasms, Placebos, Prognosis, Quinazolines, Survival Rate, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks